Adicet bio, inc. announces proposed public offering of common stock and concurrent private placement

Menlo park, calif. and boston, feb. 09, 2021 (globe newswire) -- adicet bio, inc. (“adicet”) (nasdaq: acet), a biotechnology company discovering and developing allogeneic gamma delta t cell therapies for cancer and other diseases, today announced that it has commenced an underwritten public offering of its common stock. adicet also intends to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the number of shares sold at the public offering price, less underwriting discounts and commissions. all of the shares in the proposed offering are to be sold by adicet.
ACET Ratings Summary
ACET Quant Ranking